Nicotine-induced structural plasticity in mesencephalic dopaminergic neurons is mediated by dopamine d3 receptors and akt-mtorc1 signaling

Molecular Pharmacology

Volumn 83, Issue 6, 2013, Pages 1176-1189

  Collo, Ginetta ^a   Bono, Federica ^a   Cavalleri, Laura ^a   Plebani, Laura ^a   Mitola, Stefania ^a   Pich, Emilio Merlo ^b   Millan, Mark J ^c   Zoli, Michele ^d   Maskos, Uwe ^e   Spano, PierFranco ^a   Missale, Cristina ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b Pharmaceutical Division   (Switzerland)

^c INSTITUT DE RECHERCHES SERVIER   (France)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; DIHYDRO BETA ERYTHROIDINE; DOPAMINE 3 RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MECAMYLAMINE; METHYLLYCACONITINE; MITOGEN ACTIVATED PROTEIN KINASE; N [4 [2 (6 CYANO 1,2,3,4 TETRAHYDRO 2 ISOQUINOLINYL)ETHYL]CYCLOHEXYL] 4 QUINOLINECARBOXAMIDE; NICOTINE; NICOTINIC RECEPTOR; PROTEIN KINASE B; S6 KINASE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; DOPAMINERGIC NERVE CELL; MESENCEPHALIC DOPAMINERGIC NEURON; MOUSE; NONHUMAN; ONCOGENE; PHOSPHORYLATION; PLASTICITY; PRIORITY JOURNAL;

ANIMALS; ANIMALS, NEWBORN; CELLS, CULTURED; DOPAMINERGIC NEURONS; ENZYME ACTIVATION; FEMALE; MAP KINASE SIGNALING SYSTEM; MATERNAL EXPOSURE; MATERNAL-FETAL EXCHANGE; MESENCEPHALON; MICE; MICE, KNOCKOUT; NICOTINE; PREGNANCY; PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, DOPAMINE D3; RECEPTORS, NICOTINIC; SIGNAL TRANSDUCTION;

EID: 84877796099     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.113.084863     Document Type: Article

References (58)

1. Accili D, Fishburn CS, Drago J, Steiner H, Lachowicz JE, Park B-H, Gauda EB, Lee EJ, Cool MH, and Sibley DR et al. (1996) A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci USA 93: 1945-1949. (Pubitemid 26079860)
2. Alonso M, Medina JH, and Pozzo-Miller L (2004) ERK1/2 activation is necessary for BDNF to increase dendritic spine density in hippocampal CA1 pyramidal neurons. Learn Mem 11:172-178. (Pubitemid 38456599)
3. Benowitz NL (1988) Drug therapy. Pharmacologic aspects of cigarette smoking and nicotine addition. N Engl J Med 319:1318-1330. (Pubitemid 19003394)
4. Beom SR, Cheong D, Torres G, Caron MG, and Kim KM (2004) Comparative studies of molecular mechanisms of dopamine D2 and D3 receptors for the activation of extracellular signal-regulated kinase. J Biol Chem 279:28304-28314. (Pubitemid 38900109)
5. Bublitz MH and Stroud LR (2012) Maternal smoking during pregnancy and offspring brain structure and function: Review and agenda for future research. Nicotine Tob Res 14:388-397.
6. Bunnemann B, Terron A, Zantedeschi V, Merlo Pich E, and Chiamulera C (2000) Chronic nicotine treatment decreases neurofilament immunoreactivity in the rat ventral tegmental area. Eur J Pharmacol 393:249-253. (Pubitemid 30193424)
7. Cammalleri M, Lütjens R, Berton F, King AR, Simpson C, Francesconi W, and Sanna PP (2003) Time-restricted role for dendritic activation of the mTOR-p70S6K pathway in the induction of late-phase long-term potentiation in the CA1. Proc Natl Acad Sci USA 100:14368-14373. (Pubitemid 37499243)
8. Champtiaux N, Gotti C, Cordero-Erausquin M, David DJ, Przybylski C, Léna C, Clementi F, Moretti M, Rossi FM, and Le Novère N et al. (2003) Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice. J Neurosci 23:7820-7829. (Pubitemid 37055453)
9. Changeux JP (2010) Nicotine addiction and nicotinic receptors: Lessons from genetically modified mice. Nat Rev Neurosci 11:389-401.
10. Collo G, Zanetti S, Missale C, and Spano PF (2008) Dopamine D3 receptor-preferring agonists increase dendrite arborization of mesencephalic dopaminergic neurons via extracellular signal-regulated kinase phosphorylation. Eur J Neurosci 28: 1231-1240.
11. Collo G, Bono F, Cavalleri L, Plebani L, Merlo Pich E, Millan MJ, Spano PF, and Missale C (2012) Pre-synaptic dopamine D(3) receptor mediates cocaineinduced structural plasticity in mesencephalic dopaminergic neurons via ERK and Akt pathways. J Neurochem 120:765-778.
12. Corrigall WA, Coen KM, and Adamson KL (1994) Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area. Brain Res 653:278-284. (Pubitemid 24252850)
13. Crozatier C, Guerriero RM, Mathieu F, Giros B, Nosten-Bertrand M, and Kosofsky BE (2003) Altered cocaine-induced behavioral sensitization in adult mice exposed to cocaine in utero. Brain Res Dev Brain Res 147:97-105. (Pubitemid 38114701)
14. Cussac D, Newman-Tancredi A, Pasteau V, and Millan MJ (1999) Human dopamine D(3) receptors mediate mitogen-activated protein kinase activation via a phosphatidylinositol 3-kinase and an atypical protein kinase C-dependent mechanism. Mol Pharmacol 56:1025-1030.
15. Diaz J, Pilon C, Le Foll B, Gros C, Triller A, Schwartz J-C, and Sokoloff P (2000) Dopamine D3 receptors expressed by all mesencephalic dopamine neurons. J Neurosci 20:8677-8684.
16. Doura MB, Luu TV, Lee NH, and Perry DC (2010) Persistent gene expression changes in ventral tegmental area of adolescent but not adult rats in response to chronic nicotine. Neuroscience 170:503-513.
17. Fiorentini C, Busi C, Gorruso E, Gotti C, Spano PF, and Missale C (2008) Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization. Mol Pharmacol 74:59-69. (Pubitemid 351872159)
18. Grandinetti A, Morens DM, Reed D, and MacEachern D (1994) Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson's disease. Am J Epidemiol 139:1129-1138. (Pubitemid 24184407)
19. Heidbreder CA, Gardner EL, Xi Z-X, Thanos PK, Mugnaini M, Hagan JJ, and Ashby CR, Jr (2005) The role of central dopamine D3 receptors in drug addiction: A review of pharmacological evidence. Brain Res Brain Res Rev 49:77-105. (Pubitemid 40800164)
20. Huang LZ, Campos C, Ly J, Ivy Carroll F, and Quik M (2011) Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats. Neuropharmacology 60:861-868.
21. Hyman C, Hofer M, Barde YA, Juhasz M, Yancopoulos GD, Squinto SP, and Lindsay RM (1991) BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350:230-232. (Pubitemid 21912205)
22. Kleijn J, Folgering JH, van der Hart MC, Rollema H, Cremers TI, and Westerink BH (2011) Direct effect of nicotine on mesolimbic dopamine release in rat nucleus accumbens shell. Neurosci Lett 493:55-58.
23. Kumar V, Zhang M-X, Swank MW, Kunz J, and Wu G-Y (2005) Regulation of dendritic morphogenesis by Ras-PI3K-Akt-mTOR and Ras-MAPK signaling pathways. J Neurosci 25:11288-11299. (Pubitemid 43083703)
24. Kwon CH, Zhu X, Zhang J, and Baker SJ (2003) mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo. Proc Natl Acad Sci USA 100:12923-12928. (Pubitemid 37340001)
25. Janson AM, Fuxe K, Sundström E, Agnati LF, and Goldstein M (1988a) Chronic nicotine treatment partly protects against the 1-methyl-4-phenyl-2,3,6- tetrahydropyridineinduced degeneration of nigrostriatal dopamine neurons in the black mouse. Acta Physiol Scand 132:589-591.
26. Janson AM, Fuxe K, Agnati LF, Kitayama I, Härfstrand A, Andersson K, and Goldstein M (1988b) Chronic nicotine treatment counteracts the disappearance of tyrosine-hydroxylase-immunoreactive nerve cell bodies, dendrites and terminals in the mesostriatal dopamine system of the male rat after partial hemitransection. Brain Res 455:332-345.
27. Jaworski J, Spangler S, Seeburg DP, Hoogenraad CC, and Sheng M (2005) Control of dendritic arborization by the phosphoinositide-39-kinase-Akt- mammalian target of rapamycin pathway. J Neurosci 25:11300-11312. (Pubitemid 43083704)
28. Jefferies HB, Fumagalli S, Dennis PB, Reinhard C, Pearson RB, and Thomas G (1997) Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k. EMBO J 16:3693-3704. (Pubitemid 27250062)
29. Jensen AA, Frølund B, Liljefors T, and Krogsgaard-Larsen P (2005) Neuronal nicotinic acetylcholine receptors: Structural revelations, target identifications, and therapeutic inspirations. J Med Chem 48:4705-4745. (Pubitemid 41038456)
30. Joyce JN and Millan MJ (2007) Dopamine D3 receptor agonists for protection and repair in Parkinson's disease. Curr Opin Pharmacol 7:100-105. (Pubitemid 46238043)
31. Le Foll B, Diaz J, and Sokoloff P (2005) A single cocaine exposure increases BDNF and D3 receptor expression: Implications for drug-conditioning. Neuroreport 16:175-178. (Pubitemid 40250395)
32. Le Foll B, Goldberg SR, and Sokoloff P (2007) Dopamine D3 receptor ligands for the treatment of tobacco dependence. Expert Opin Investig Drugs 16:45-57. (Pubitemid 44964166)
33. Mannoury la Cour C, Salles MJ, Pasteau V, and Millan MJ (2011) Signaling pathways leading to phosphorylation of Akt and GSK-3b by activation of cloned human and rat cerebral D?and D? receptors. Mol Pharmacol 79:91-105.
34. Marubio LM, Gardier AM, Durier S, David D, Klink R, Arroyo-Jimenez MM, McIntosh JM, Rossi F, Champtiaux N, and Zoli M et al. (2003) Effects of nicotine in the dopaminergic system of mice lacking the alpha4 subunit of neuronal nicotinic acetylcholine receptors. Eur J Neurosci 17:1329-1337. (Pubitemid 36560833)
35. McAllister AK, Katz LC, and Lo DC (1999) Neurotrophins and synaptic plasticity. Annu Rev Neurosci 22:295-318. (Pubitemid 29144890)
36. Missale C, Nash SR, Robinson SW, Jaber M, and Caron MG (1998) Dopamine receptors: From structure to function. Physiol Rev 78:189-225. (Pubitemid 28070979)
37. Mudo G, Belluardo N, and Fuxe K (2007) Nicotinic receptor agonists as neuroprotective/ neurotrophic drugs. Progress in molecularmechanisms. J Neural Transm114:135-147. (Pubitemid 46018681)
38. Mueller D, Chapman CA, and Stewart J (2006) Amphetamine induces dendritic growth in ventral tegmental area dopaminergic neurons in vivo via basic fibroblast growth factor. Neuroscience 137:727-735. (Pubitemid 43053938)
39. Nestler EJ, Hope BT, and Widnell KL (1993) Drug addiction: A model for the molecular basis of neural plasticity. Neuron 11:995-1006. (Pubitemid 24015274)
40. Picciotto MR, Zoli M, Rimondini R, Léna C, Marubio LM, Pich EM, Fuxe K, and Changeux JP (1998) Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature 391:173-177. (Pubitemid 28092475)
41. Quarta D, Ciruela F, Patkar K, Borycz J, Solinas M, Lluis C, Franco R, Wise RA, Goldberg SR, and Hope BT et al. (2007) Heteromeric nicotinic acetylcolinedopamine autoreceptor complexes modulate striatal dopamine release. Neuropsycopharmacology 32:35-42. (Pubitemid 44967782)
42. Quik M, Parameswaran N, McCallum SE, Bordia T, Bao S, McCormack A, Kim A, Tyndale RF, Langston JW, and Di Monte DA (2006) Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates. J Neurochem 98:1866-1875. (Pubitemid 44313641)
43. Quik M, Perez XA, and Bordia T (2012) Nicotine as a potential neuroprotective agent for Parkinson's disease. Mov Disord 27:947-957.
44. Rahman S, Zhang J, and Corrigall WA (2004) Local perfusion of nicotine differentially modulates somatodendritic dopamine release in the rat ventral tegmental area after nicotine preexposure. Neurochem Res 29:1687-1693. (Pubitemid 39070058)
45. Reperant C, Pons S, Dufour E, Rollema H, Gardier AM, and Maskos U (2010) Effect of the a4b2* nicotinic acetylcholine receptor (nAChR) partial agonist varenicline on dopamine release: A study in b22/2 mice with selective re-expression of the b2 nAChR subunit in the ventral tegmental area. Neuropharmacology 58:346-350.
46. Rollema H, Hajós M, Seymour PA, Kozak R, Majchrzak MJ, Guanowsky V, Horner WE, Chapin DS, Hoffmann WE, and Johnson DE et al. (2009) Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition. Biochem Pharmacol 78:813-824.
47. Russo SJ, Dietz DM, Dumitriu D, Morrison JH, Malenka RC, and Nestler EJ (2010) The addicted synapse: Mechanisms of synaptic and structural plasticity in nucleus accumbens. Trends Neurosci 33:267-276.
48. Sarti F, Borgland SL, Kharazia VN, and Bonci A (2007) Acute cocaine exposure alters spine density and long-term potentiation in the ventral tegmental area. Eur J Neurosci 26:749-756. (Pubitemid 47206790)
49. Scheidenhelm DK, Cresswell J, Haipek CA, Fleming TP, Mercer RW, and Gutmann DH (2005) Akt-dependent cell size regulation by the adhesion molecule on glia occurs independently of phosphatidylinositol 3-kinase and Rheb signaling. Mol Cell Biol 25:3151-3162. (Pubitemid 40464317)
50. Schmidt U, Beyer C, Oestreicher AB, Reisert I, Schilling K, and Pilgrim C (1996) Activation of dopaminergic D1 receptors promotes morphogenesis of developing striatal neurons. Neuroscience 74:453-460. (Pubitemid 26274215)
51. Searle G, Beaver JD, Comley RA, Bani M, Tziortzi A, Slifstein M, Mugnaini M, Griffante C, Wilson AA, and Merlo-Pich E et al. (2010) Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist. Biol Psychiatry 68:392-399.
52. Sokoloff P, Leriche L, Diaz J, Louvel J, and Pumain R (2013) Direct and indirect interactions of the dopamine D? receptor with glutamate pathways: Implications for the treatment of schizophrenia. Naunyn Schmiedebergs Arch Pharmacol 386:107-124.
53. Van Kampen JM and Eckman CB (2006) Dopamine D3 receptor agonist delivery to a model of Parkinson's disease restores the nigrostriatal pathway and improves locomotor behavior. J Neurosci 26:7272-7280.
54. Vezina P, McGehee DS, and Green WN (2007) Exposure to nicotine and sensitization of nicotine-induced behaviors. Prog Neuropsychopharmacol Biol Psychiatry 31: 1625-1638. (Pubitemid 47625708)
55. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, and Mandel J (2011) Epidemiology and etiology of Parkinson's disease: A review of the evidence. Eur J Epidemiol 26 (S1): S1-58.
56. Wonnacott S, Kaiser S, Mogg A, Soliakov L, and Jones IW (2000) Presynaptic nicotinic receptors modulating dopamine release in the rat striatum. Eur J Pharmacol 393:51-58. (Pubitemid 30193400)
57. Zhao-Shea R, Liu L, Soll LG, Improgo MR, Meyers EE, McIntosh JM, Grady SR, Marks MJ, Gardner PD, and Tapper AR (2011) Nicotine-mediated activation of dopaminergic neurons in distinct regions of the ventral tegmental area. Neuropsychopharmacology 36:1021-1032.
58. Zoli M, Le Novère N, Hill JA, Jr, and Changeux JP (1995) Developmental regulation of nicotinic ACh receptor subunit mRNAs in the rat central and peripheral nervous systems. J Neurosci 15:1912-1939.